Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
SEC to eventually approve spot Ethereum ETFs, says JPMorgan

SEC to eventually approve spot Ethereum ETFs, says JPMorgan

The BlockThe Block2024/04/05 16:43
By:Yogita Khatri

JPMorgan predicts eventual SEC approval for spot Ethereum ETFs.The SEC is currently soliciting comments for a handful of spot ETH ETF applications.

SEC to eventually approve spot Ethereum ETFs, says JPMorgan image 0JPMorgan remains optimistic about the Securities and Exchange Commission's eventual approval of spot Ethereum ETH -1.77% exchange-traded funds despite earlier this year assigning not more than a 50% chance for approval by May, the initial deadline.

"If there is no spot Ethereum ETF approval in May, then we assume there is going to be a litigation process after May," Nikolaos Panigirtzoglou, managing director and global market strategist at JPMorgan, told The Block. "We believe that the most likely scenario is that the SEC eventually loses this litigation (similar to what happened with the Grayscale and Ripple legal battles last year), which means that eventually, the SEC will approve spot Ethereum ETFs (but not as soon as this May)."

Notably, Panigirtzoglou has kept the odds of May approval at 50% despite recent reports suggesting the SEC is investigating the Ethereum Foundation and actively seeking to classify ether (ETH) as a security through legal avenues.

Earlier this week, Panigirtzoglou and his team said in a report that Ethereum's easing centralization concerns (such as Lido's decreasing market share) raise the chance that ETH will avoid being designated as a security in the future. The team pointed out that network decentralization plays a role in determining the classification of a digital token as a security, as highlighted by the SEC's release of the "Hinman documents" last June.

Diminished hope for May approval

Several analysts have decreased their optimism regarding the SEC's potential approval for a spot ether ETF by May. Last week, Bloomberg senior ETF analyst Eric Balchunas, for instance, said his odds for May approval remain pessimistic at 25%, down from 70% in January.

The SEC is currently soliciting comments on a handful of spot ETH ETF applications, including from Fidelity, Grayscale and Bitwise. Comments for all three are due later this month.

2
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales